Welcome to CDC stacks | SARS Vaccine Protective in Mice - 14732 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
SARS Vaccine Protective in Mice
  • Published Date:
    Aug 2005
  • Source:
    Emerg Infect Dis. 11(8):1312-1314.
Filetype[PDF-53.71 KB]


No Related Documents.
You May Also Like:
  1. SARS Vaccine Development
    Personal Author:
    Jiang, Shibo; He, Yuxian; Liu, Shuwen;
    Published:
    Jul 2005
    Source:
    Emerg Infect Dis. 11(7):1016-1020.
    Description:
    Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it ...
    File Type:
    Filetype[PDF - 95.26 KB]
  2. Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases
    Personal Author:
    Fauci, Anthony S.; Touchette, Nancy A.; Folkers, Gregory K.;
    Published:
    Apr 2005
    Source:
    Emerg Infect Dis. 11(4):519-525.
    Description:
    Although optimists once imagined that serious infectious disease threats would by now be conquered, newly emerging (e.g., severe acute respiratory syndrome [SARS]), reemerging (e.g., West Nile virus), and even deliberately disseminated infectious dis...
    File Type:
    Filetype[PDF - 228.68 KB]
  3. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
    Personal Author:
    Temperton, Nigel J.; Chan, Paul K.; Simmons, Graham; Zambon, Maria C.; Tedder, Richard S.; Takeuchi, Yasuhiro; Weiss, Robin A.;
    Published:
    Mar 2005
    Source:
    Emerg Infect Dis. 11(3):411-416.
    Description:
    The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay...
    File Type:
    Filetype[PDF - 203.46 KB]
  4. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
    Personal Author:
    Excler, Jean-Louis; Delvecchio, Christopher J.; Wiley, Ryan E.; Williams, Marni; Yoon, In-Kyu; Modjarrad, Kayvon; Boujelal, Mohamed; Moorthy, Vasee S.; Hersi, Ahmad Salah; Kim, Jerome H.;
    Corporate Author:
    on behalf of the MERS-CoV Vaccine Working Group
    Published:
    August 2016
    Source:
    Emerg Infect Dis. 22(8)
    Description:
    Middle East respiratory syndrome (MERS) remains a serious international public health threat. With the goal of accelerating the development of countermeasures against MERS coronavirus (MERS-CoV), funding agencies, nongovernmental organizations, and r...
    File Type:
    Filetype[PDF - 823.75 KB]
  5. Neutralizing Antibody Response and SARS Severity
    Personal Author:
    Ho, Mei-Shang; Chen, Wei-Ju; Chen, Hour-Young; Lin, Szu-Fong; Wang, Min-Chin; Di, Jiali; Lu, Yen-Ta; Liu, Ching-Lung; Chang, Shan-Chwen; Chao, Chung-Liang; King, Chwan-Chuen; Chiou, Jeng-Min; Su, Ih-Jen; Yang, Jyh-Yuan;
    Published:
    Nov 2005
    Source:
    Emerg Infect Dis. 11(11):1730-1737.
    Description:
    Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between w...
    File Type:
    Filetype[PDF - 350.84 KB]